Intrinsiqs

Is Aktis Oncology, Inc. overvalued?

Aktis Oncology, Inc. (AKTS) — key valuation metrics and fundamentals.

No verdict
Price
$16.62
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$893.3M
Dividend yield
0.0%
Return on equity
-26.9%
Sector
Healthcare

See the full interactive analysis →

Fair value compares AKTS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.